Rasio utang jangka dawa marang modal Xencor Inc. (XNCR)

Xencor, Inc. (XNCR) creates innovative protein structures using its proprietary antibody optimization system. The company generates revenue by providing its developments to pharmaceutical behemoths, receiving stable royalties. Income is based on upfront payments for access to technologies targeting tumors and autoimmune pathologies. The current figure is 0.26. This chart of the market price illustrates the asset value dynamics for this developer.

It is critically important for Xencor, Inc. (XNCR) to maintain financial autonomy while the peak development of XmAb bispecific antibodies requires colossal expenditures for clinical trials. Analyzing the ratio of long-term debt to equity allows for the filtering of market noise, assessing the real stability of the balance sheet and protection against delisting by comparing long-term liabilities with the company's base capital.